
Des chercheurs ont identifié des biomarqueurs chez les patients obèses atteints « maladie du foie gras » expliquant ce risque plus élevé de maladie sévère.
Des chercheurs ont identifié des biomarqueurs chez les patients obèses atteints « maladie du foie gras » expliquant ce risque plus élevé de maladie sévère.
Pour la première fois, des chercheurs du laboratoire de recherche « Ingénierie moléculaire et physiopathologie articulaire » (Cnrs/Université de Lorraine) et du laboratoire « Défaillances cardiovasculaires aiguë et chronique » (Inserm/Université de Lorraine) à Nancy, ont décrit le développement spontané de ce type d’arthropathie dégénérative dans un modèle murin de SMet.
POMC (proopiomelanocortin) deficiency obesity is an orphan disease which has been described in 50 patients to date, although it is estimated to affect 100–500 people worldwide. Although there is currently no specific treatment, a publication in NEJM reports promising results from a phase 2 clinical trial that led to considerable weight loss in female patients.
In this work, carried out by researchers from Inserm and the French National Institute for Agricultural Research (INRA), in collaboration with researchers from the University of Vienna, Austria, a fragment of Der p 2 was generated by genetic engineering, and its protective effect against house dust mite asthma was then tested in a mouse model of asthma.
In a new study published in The American Journal of Respiratory Cell and Molecular Biology, Olivier Meilhac’s team (Inserm Unit 1148, the “Laboratory for Vascular Translational Science,” in collaboration with Inserm Unit 1152, “Physiopathology and Epidemiology of Respiratory Diseases”) addressed the transport capability of HDLs (high density lipoproteins, commonly known as “good cholesterol”)
Leptin is a hormone secreted by adipose cells, sending the satiety signal to the brain. Sometimes, certain overweight or obese individuals develop resistance to this hormone, which is no longer able to deliver its message.